Pravastatin detailed information

Revision as of 18:18, 27 September 2011 by WikiBot (talk | contribs) (Protected "Pravastatin detailed information": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Pravastatin detailed information
Clinical data
ATC code
Pharmacokinetic data
Protein binding50%
Elimination half-life77 hours
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC23H36O7
Molar mass424.528 g/mol

WikiDoc Resources for Pravastatin detailed information

Articles

Most recent articles on Pravastatin detailed information

Most cited articles on Pravastatin detailed information

Review articles on Pravastatin detailed information

Articles on Pravastatin detailed information in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pravastatin detailed information

Images of Pravastatin detailed information

Photos of Pravastatin detailed information

Podcasts & MP3s on Pravastatin detailed information

Videos on Pravastatin detailed information

Evidence Based Medicine

Cochrane Collaboration on Pravastatin detailed information

Bandolier on Pravastatin detailed information

TRIP on Pravastatin detailed information

Clinical Trials

Ongoing Trials on Pravastatin detailed information at Clinical Trials.gov

Trial results on Pravastatin detailed information

Clinical Trials on Pravastatin detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pravastatin detailed information

NICE Guidance on Pravastatin detailed information

NHS PRODIGY Guidance

FDA on Pravastatin detailed information

CDC on Pravastatin detailed information

Books

Books on Pravastatin detailed information

News

Pravastatin detailed information in the news

Be alerted to news on Pravastatin detailed information

News trends on Pravastatin detailed information

Commentary

Blogs on Pravastatin detailed information

Definitions

Definitions of Pravastatin detailed information

Patient Resources / Community

Patient resources on Pravastatin detailed information

Discussion groups on Pravastatin detailed information

Patient Handouts on Pravastatin detailed information

Directions to Hospitals Treating Pravastatin detailed information

Risk calculators and risk factors for Pravastatin detailed information

Healthcare Provider Resources

Symptoms of Pravastatin detailed information

Causes & Risk Factors for Pravastatin detailed information

Diagnostic studies for Pravastatin detailed information

Treatment of Pravastatin detailed information

Continuing Medical Education (CME)

CME Programs on Pravastatin detailed information

International

Pravastatin detailed information en Espanol

Pravastatin detailed information en Francais

Business

Pravastatin detailed information in the Marketplace

Patents on Pravastatin detailed information

Experimental / Informatics

List of terms related to Pravastatin detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

For patient information, click here

Overview

In medicine and pharmacology, pravastatin (Pravachol® or Selektine®) is a member of the drug class of statins, used for lowering cholesterol and preventing cardiovascular disease.

Pravastatin was identified originally in a bacterium called Nocardia autotrophica by researchers of the Sankyo Pharma Inc. It is presently being marketed outside Japan by the pharmaceutical company Bristol-Myers Squibb.

In 2003, Bristol-Myers Squibb announced in a magazine advertisement that pravastatin is no longer the only statin approved by the FDA proven to reduce the risk of cardiovascular disease, and that rosuvastatin, another statin, is approved to reduce this risk.

The U.S. Food and Drug Administration approved a generic version of Pravastatin for sale in the United States for the first time on April 24, 2006. Generic Pravastatin Sodium Tablets (10mg, 20mg and 40mg) are manufactured by TEVA Pharmaceuticals in Kfar Sava, Israel. FDA Press Release

In 2005, Pravachol was the 22nd highest-selling brand-name drug in the United States. FDA Press Release

External links

Template:Statins Template:SIB hu:Pravasztatin nl:Pravastatine th:ปราวาสแตติน


Template:WikiDoc Sources